Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Carl Icahn Exercises Options and Reiterates Stake in Hologic, Inc. (HOLX)

Activist Carl Icahn has reiterated his position in Hologic, Inc. (NASDAQ:HOLX) following the exercise of call options held earlier. According to SEC filings, Icahn acquired 30.6 million shares under the options, and currently owns in aggregate 34.2 million shares. The securities under the option have been purchased at a price of $14.5 per share, the aggregate amount spent raising to $444.1 million.

Carl Icahn

According to a filing, Mr. Icahn has spent a total of $729.2 million on acquiring his stake in Hologic, Inc. (NASDAQ:HOLX). Currently the billionaire holds 12.51% of the company’s common stock. The “hedgie” has already disclosed earlier that he intends to negotiate with the company’s management regarding the possibility to increase the value of the company for its shareholders.

As a first step, Icahn entered into an agreement with the company’s board, following which he got to nominate two representatives on Hologic, Inc. (NASDAQ:HOLX)’s board, Mr. Jonathan Christodoro and Mr. Samuel Merksamer.

Icahn initiated a position in Hologic, Inc. (NASDAQ:HOLX) earlier in November. Amid the announcement made by Icahn to acquire a stake in Hologic, the company decided to adopt an one-year stockholder rights plan, or also known as the Poison Pill. According to the plan, stockholders will be able to receive one right for one share of the company’s common stock, and will be exercisable only if a person or a group buys more than 10% of the Hologic, Inc. (NASDAQ:HOLX)’s common stock.  The plan was adopted in order to prevent the possibility of a hostile takeover.

John A. Levin’s Levin Capital Strategies, and Barry Rosenstein’s Jana Partners are two other shareholders of Hologic, Inc. (NASDAQ:HOLX), which in the latest round of 13F filings revealed 4.6 million shares, and 3.6 million shares respectively.

A couple of days ago, Mr. Icahn also revealed boosting his stake in Nuance Communications Inc. (NASDAQ:NUAN). The billionaire purchased around 1.4 million shares, raising the holding to a total of 60.3 million, equal to 19.2% of the company’s common stock.

Disclosure: none

Recommended Reading:

Hedge Fund News: David Tepper, George Soros & Man Group

GAMCO Goes Activist on Ascent Capital Group Inc (ASCMA); Proposes a Vote Regarding the Company’s Poison Pill

Anadarko Petroleum Corporation (APC), Schlumberger Limited. (SLB) Among 5 Energy Stocks That Hedge Funds Love

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!